Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study  by Kielman, Neal S et al.




Mechanisms of Early Death Despite Thrombolytic Therapy :
Experience From the Thrombolysis in Myocardial Infarction
Phase II (TIMI II) Study
NEAL S . let FTM9N, MD, FACC, MICHAEL TERRIN . MD, MPH .
HILTRUD MUELLER, MD, FACC, BERNARD CHAITMAN . MD, FACC,
ROBERT ROBERTS, MD, FACC, GENELL L . KNATTERUD, PHD, RACHEL SOLOMON, MHS,
ROBERT P. McMAHON, PHD, EUGENE BRAUNWALD . MD, FACC,
AND THE TIMIINVESTIGATORS*
Baltimore, Marylond
Mechanisms of death among patients who died within IS h of
enrollment in the Thrombolysis in Myocardial Infarction Phase 11
(TIMI 11) study were analyzed . 00,339 patients enrolled, 32 died
within the 1st 4 h and 31 died within the subsequent 14 h . Thirteen
of the 63 patients had shock at enrollment ; 22 had advanced
hemodynamic compromise without shock and 28 initially had
minimal to no compromise .
Prior infarction was present in 16 patients (25%) . Pump
failure was responsible for 39 early deaths (62%), ventricular
rupture for 10 (16%), arrhythmia for S 113%) and complications
of therapy Bar 6 (10%r). Nine of 720 patients randomized to
Thrombolytic therapy for patients with acute myocardial
infarction has greatly improved the prognosis associated
with this syndrome (1-4). The mortality rate among patients
enrolled in trials of thrombolytic therapy is currently be-
tween 5% and 9%
(4
.5) . As further advances in the treatment
of myocardial infarction occur, any further decline in the
already tow mortality will become increasingly difficult to
establish . To be most effective, future refinements in reper-
fusion therapy will need to be targeted toward the clinical
presentations preceding, and the mechar,isnts responsible
for, the majority of deaths
. Previous studies (6,7)
indicated
that most of the deaths after thrombolytic therapy occur
soon after patient presentation and suggested that throm-
bolytic therapy may not prevent death during the Lt day
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immediate intravenous beta-adrenergic blacking agent therapy
had an early death compared with 6 of 714 assigned to deferred
bom•h lorker therapy .
Thus, mortality is highest in the early hours after myocardial
infarction, even in patients treated with thromboytic therapy and





efforts to reduce mortality during this critical time period should
be directed at prevention, limitation or Inflation of early pump
failure .
(J
Am Call Cordial 1992
;1"129-35)
after infarction. If patients likely to die during this period
could be identified with reasonable precision, adjunctive or
more aggressive therapy might be selected promptly and
applied with a more beneficial outcome . This study was
therefore undertaken to analyze early deaths among patients
receiving intravenous recombinant tissue-type plasminogen
activator (rt-PA) in the Thrombolysis in Myocardial Infarc-
tion Phase 11 (TIMI 11) study .
Methods
Study protocol. The design of the trial has been reported
previously (8) .
The study protocol was approved by the
itstional Rcv(ew Board of each participating center, and
all participating subjects gave informed consent
. Briefly, 24
clinical centers participated in the study . Patients were
eligible for enrollment if they fulfilled the following criteria :
I) age s76 years, 2) chest discomfort suggestive of acute
myocardial ischemia lasting a30 min, 3) ST segment ele-
vation a0.1 mV in two electrically contiguous leads, and
4) presentation within 4 h after the onset of chest pain
.
Patients were excluded from the trial for a history of stroke
or cerebrovascular disease, systolic blood pressure
>180 mm Hg or diastolic blood pressure >110 mm Hg, a
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2 weeks, recent card opulmonary, resusc tat on, percutane-
ous translum nal coronary ang oplasty or severe trauma
w th n the prev ous 6 months, pr or coronary artery bypass
surgery or prosthet c heart valve replacement, left bundle
branch block, d lated card omyopathy or other ser ous ll-
ness.
Intravenous rt-PA was adm n stered over a per od of 6 h .
For 520 pat ents the ntended dosage was 150 ITS, and for the
subsequent 2,819 pat ents, the ntended dosage was 100 mg.
Hepar n was g ven as an ntravenous bolus nject on of
5,000 U followed by an nfus on of 1,000 Ulh.
Beta-adrenerg c block ng agent el g b l ty . Pat ents were
el g ble for a random zed substudy of
mmed ate ntravenous
compared w th oral beta-adrenergc block ng agent therapy
(TIMI IIB) f they were not alreads rece v ng a beta-blocker,
verapam l ord
lt
azem and d d not have a contra
nd cat on to
beta-adrenerg
c blockade . Intravenous metoprolol was ad-
m n stered as a ser es of three bolus doses of 5 mg separated
by 2 m n and followed by oral beta-blocker therapy ; deferred
oral beta-blocker therapy began 6 days after study entry (9) .
Class fcat on of death and cln cal character st
cs
. All
deaths were reported to the Coord nat ng Center and were
rev ewed by a Mortal ty and Morb d ty Class f cat on Com-
m ttee, wh ch cons sted of persons who were not assoc ated
w th cl n cal centers and who had no knowledge of the
pat ents' treatment ass
gnments
. Mechan sms of death clas-
s f ed by the comm ttee ncluded I) ventr cular rupture, 2)
pump fa lure, and 3) arrhythm a . The Mortal ty and Morb d-
ty Class
f cat on Comm ttee could
dent
fy any of all of these
mechan sms as contr butors to a pat ent's death . Ass gnment
of the pr mary mechan sm of card ac death was based on the
degree to wh ch the mechan sm would be rrevers ble n a
card ac care sett ng .
In th s analys s, ventr cular rupture was cons dered the
pr mary mechan sm of death whenever ev
dence (d rect
v sual zat on of the heart or sudden card ac death nclud ng
electromechan cal d ssoc at on n the sett ng of cont nuously
mon tored and normal blood pressure and electr cal rhythm)
for ventr cular rupture was present . Pump fa lure was con-
s dered the pr mary mechan sm for pat ents w th progress ve
hypotens on, no extracard ac et ology and no ev dence of
card ac rupture
. Arrhythm a was cons dered the pr mary
mechan sm when t was observed n the absence of both
ventr
cular rupture and pump fa lure . Fatal compl cat ons of
therapy, such as hemorrhag c or operat ve compl
cat
ons,
were also class fed .




r sk" f they had one of
the
follow ng ct n cal character st cs: age ?70 years, pr or myo-
card al nfarct on, anter or myocard al nfarct on, rates over




atr al f br llat on or flutter. pulmonary edema or card
ogen c
shock . Shock was cons dered present
f the systol c blood
pressure was
m85
mm Hg w th ev dence of t ssue hypoper-
fus
on and was nterpreted on n t al evaluat on to be a
consequence of left ventr cular dysfunct on
. In the TIMI ll








T me From Study Start of DeathslI,IIO
Entry Noo or Deaths Per od Pat ent-Hours
54 h 32 3,339 2.41









Mortal ofOperatlons, normal zat on of ST segment abnor-
mal
t es was defned as "return of ST segments to or qu te
close to basel ne" on cl n cal center staff observat on.
In plann ng th s analys s, pat ents were cons dered to
have hemodvnam
c comprom




one of thefllon' ng character st cs was present : pulmonary
edema on chest rad ography . rates over >113 of the lung
f elds, hypotens on (systol c blood pressure <100 mm Hg)
w th s nus tachycard a (s nus rate >100 beats/m n) or sec-
ond- or th rd-degree atr oventr cular black.
Earl' death was cons dered to have occurred between the
t me of study enrollment and the beg nn ng of the t me durng
wh ch randomly ass gned nvas ve strategy (that s, catheter-
zat on and, f feas ble, coronary ang oplasty) was to have
begun (18 h after study entry) . Because the major ty of
occluded nfarct vessels that ach eve reperfus on do so
w th n the f rst few hours after treatment w th a thrombolyt c
drug (10,11) . the group w th early death was further d chot-
om





ty values for percentages
were calculated by us ng standard ch -square tests (12). To
adjust for mult ple test ng, a probab l ty value between 0.01
and 0 .001 for two-s ded tests has been spec fed as prov d ng
some ev dence of d fferences, and probab l ty values <0 .1101
have been spec f ed as prov d ng strong ev dence of d ffer-
ences . To est mate the rates at wh ch deaths occurred, a
p ecew se exponent al surv val model (13) was developed at
the t me of the analys s. It was assumed that mortal ty
rema ned constant w th n the ntervals 0 to 4 h, 4 to 18 h, 18 h
to 14 days and 14 days to 42 days after study entry . W th n
each nterval, the rate was est mated by the method of
max mal l kel hood. The est mated death rate was calculated
as the number of deaths n the nterval d v ded by the total
t me of pat ent follow-up n the nterval . Relat ve r sks were
est
mated w
th standard methods for proport ons, and 99%
confdence ntervals for the relat ve r sks were est mated by
us ng a Taylor ser es approx mat on (12,13). All stat st cal
analyses were conducted w th the Stat st cal Analys s Sys-
tem ISAS) software package (14) and the TIMI 11 analys s
f le of September 1990 .
Results
Study pat ents (Tables I and 21. A total of 3,339 pat ents






. Actual r-PA Dose Rece ved Accord ng to
Length of Surv val
'p 10.001 . n-PA - recomb nard t ssue-type plasm nogen act vator,
w th n the 1st 6 weeks . S xty-three pat ents (1 .9%) d ed
w th n the 1st 1S h after enrollment and form the bas s of the
present report . Four of the 63 pat ents underwent coronary
arter ography, nclud
ng 3 who underwent emergency ang o-
plasty and 2 who underwent emergency bypass surgery .
Mortal ty (deaths/1,000 pat ent-hours) accord ng to t me
from study entry s shown n Table 1 .
Th
rty-two (50%)
of the 63 early deaths occurred w th n
the lot 4 h and 41 (65%) occurred before the prescr bed 6-h
nfus on of rt-PA could be completed
. F
fteen (47%) of the
32 pat ents who d ed w th n 4 h rece ved <80 mg of n-PA
compared w th 4 (13%) of 31 pat ents who d ed between
4 and 18 h after study entry and 22 (0.6%) of 3,276 pat ents
who surv
val for 18 h (Table 2) and rece ved <80 mg of
rt-PA. Among pat ents who d ed w
th
n the 1st 4 h . the
reasons for premature term nat on of the nfus on were death
or card ac arrest n 26 pat ents (81%), hypotens on n 3 (9%)
and bleed
ng or m scellaneous compl cat ons n 2 (6%). One
pat ent (3%) rece ved the full dose
. Among 31 pat ents who
d ed between 4 and 18 h after study entry, the nfus
on was
nterrupted n 15 (48%) because of death or card
ac arrest
n 9 pat ents (29%), card ogen e shock n 2 (6%), bleed ng n
1 (3%), nvas ve procedures n 2 (6%) and unreported rea-
sons n I pat ent (3%) . S xteen pat ents (52%) who d ed n
th s nterval rece ved the full dose . The n-PA nfus on was




frequent reasons were bleed ng n 37 pat ents (1%), techn cal




ovascular, neurolog c and other
compl cat ons) n 22 (1%). Reasons for nterrupt on of the
nfus on were not ava lable n 7 pat ents (0.2%) who surv ved
>18 h .
Clncal character st cs ITable 3). At the t
me of study
entry, 57 (90%) of the pat ents w th early death were n the
"not low rsk" category, 43 (68%) had anter or wall myo-




c shock and 13 (21%) were n
card ogen c shock. The mean tme from the onset of symp-
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pat ents who d
ed w th n 18 h compared w th 2 .6 ± 0 .8 b n
pat
ents who surv ved >18 h (p = 0.30) .
There were 13 early deaths (26%) among 50 pat ents w th
shock . 22 (5 .9%) among 375 pat
ents w th hemodynam c
comprom se but w thout shock and 28 (1%) among 2
.914
pat ents present ng w th l ttle or no hemodynam c compro-
m se . The
nd
v
dual characterst cs assoc ated w th the
h ghest frequency of early death were shock
n 13 (26%) of
50, rad
ograph c ev dence of pulmonary edema n 4 (11 .5%)
of 34, rules over >113 of the lung f elds on n t al exam nat on
n 13 (9.5%) of 134, hypotens on w
th s nus tachycard a n 17
(9%) of 187 and a h story of per pheral vascular d sease n 9
(R%) of 115
. The character st cs of pat ents who d ed w th n
4 h of study entry were s m lar to those of pat ents who d ed
between 4 and 18 h after study entry
.
Cl n cal response to rt-PA nfus on (Table 4) . Rel ef of
chest pa n, normal zat on of ST segment dev at on and
ncrease
n blood pressure were less common dur ng n-PA
nfus on among pat ents who d
ed early than among those
who surv ved the 1st 18 h; worsen ng of chest pa n. exacer-
bat on of ST segment dev at on and decrease n blood
pressure were more common n the group who d ed early.
Among the 44 pat ents who d
ed early and who had a
reported decrease n blood pressure, the decrease pre-
ceded death by s30 m n n I pat ent (2%), by >30 m n but





ty Classfcat on Commttee class f-
cat ons of causes and
mechan sm of death (Tables 5 and 6) .
Pump fa lure was the most common mechan sm of early
death, account ng for 62% of cases (Table 5) . Ventrcular
rupture accounted for 16% and arrhythm a 13%. Compl ca-
t ons of therapy result ng
n death w
th
n 18 h of study entry
ncluded three gastro ntest nal hemorrhages and two hemor-
rhages nto soft t ssue compartments (the med ast num and
the retroper tuneum) . One pat ent d ed w th n 18 h of study
entry of compl catons of coronary artery bypass graft sur-
gery (fa
lure to wean from card opulmonary bypass followed




In 28 of the 63 pat ents who d ed early, the per card
um
was exam ned e ther at autopsy (27 pat ents) or at operat on
(I pat ent). Ventr cular rupture was d agnosed n seven
(25%) of these pat ents . In three pat ents whose percard
um
was r: : actually exam ned, ventrcular rupture was dent -
fed on the bas s of cl n cal events. There were no d fferences
n mechan sm of death among pat ents who d ed <4 h or
between 4 and 18 h .
The mechan sm of death accord ng to hemodynam c
status at study entry s shown
n Table 6
. Pump fa lure
accounted for >80% of deaths among pat ents w th hemo-
dynam c comprom se and card ogen c shock and for nearly
39% of the deaths n pat ents w thout major hemodynam c
comprom se. Ventr cular rupture was the mechan sm of
death for a 1?rger proport on of the pat ents w thout hemo-













40-59 3(9.41 1(33) 410.1)
60-79 9)28.1) 2(6 .4) 16(0.51
80-99 1300.61 10132.31 5111 .61
100 2 116 .2) 14 (45 .2) 2 .698 (92.4)
101-149 2 (6.2) 1 (3 .2) 19(9 .61
0150 0 (0.0) 206 .4) 486 (14.81
Total
32 31 3.276
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Table 3
. basel ne Character st cs Accord
ng to Occurrence of Early Death (s18 h)
class fed mechan
sm
of early death between pat
ents w
th





spons ble for death n 28 (65%) of 43 pat ents w th anter or
and Il (55%) of 20 pat ents w th nonanter or nfarct on ;
ventr cular rupture occurred n 7 (16%) of 43 and 3 (15%) of
20 pat ents, respect vely .
T m ng
of beta-blocker therapy. Treatment. results n
the 1,434 pat ents enrolled n the TIMI IIB study were




ate ntravenous beta-blocker therapy, 9
(1 .2%) d ed early, 8 of whom rece ved the ass
gned ntrave-
nous metoprolol ; 6 (0 .8%) of the 714 pat ents ass gned to
deferred beta-blocker therapy d ed w th n the 1st 18 h .
Mechan sms of card ac death among pat ents ass
gned to




lure n fve (0 .7%)
and arrhythm a n one
(0 .1%) . Among pat ents ass gned to
deferred beta-blocker therapy, ventr cular rupture was the
mechan sm of death n two (0.3%), pump fa lure
n one
(0.1%), arrhythm a n two (0.3%) and compl cat ons of
therapy n one (0.1%) .
`H story smles ng for one pat ent who d ed <_ 18 h aflerstudy cnuy.''H story data arc m ss ng far 6 pat ents who
d ed s I8 h after study envy. tCompar restr cted to pat ents w th anter or myocard al nfarct on. CHF =
congest ve heart fa lure: Cl = confdence nterval : MI = myocard al nfarct on : 0-PA = recomb nant t ssue-type
plasm nogen acl vetor. STE = ST segment elevat on : S, = Th rd heart sound.
1ACC Val. 19, No .6
May 1992 :1129-35
D scuss on
As mprovements are made n reperfos on therapy for
pat ents w th acute myocard al nfarct on . the most mpor-




. Our study s the f
rst deta led
exam nat on of the t me of greatest r sk of mortal ty and s
based on prospect vely acqu red data from pat ents rece v ng
thrombolyt c therapy. Our most mportant f nd ngs are that
the greatest mortal ty occurs w
th
n the frst hours after the
onset of acute myocard al nfarct on and treatment w th
thrombolyt c therapy and that mortal ty decreases very
rap
dly thereafter. More than 90% of early deaths occurred
among pat ents n the "not low r sk -" category and >50%
were among pat ents who had already developed cl n cal
s gns of heart fa lure by the t me of n t al evaluat on. Pump
fa lure was the most common mechan sm of death, even
among pat ents who n t ally appeared well compensated
.
Card ac rupture. Card ac rupture occurred n 16% of our
study pat ents who d ed early and was d agnosed more











Relat ve R sk
199% CD
Male gender






2 .893 (88 .3)
0 .9 (0 .3 . 2.41
Not low r sk 57190 .51 2 .169 (66 .21 4 .8 (1 .6 . 14.31
Age 070 yr 21 (33 .3) 368 111._'1 3.8 (1 .9 . 7.4)
Pr or MI 16125 .41 450(13.71 2.10.0 . 4.4)
Anter or MI 43168 .21 1 .687 (51 .51 2 .0 (1 .0.4 .0)
Rate, over >113 of lung felds 13 (211 .6) 121 (3 .7) 6 .2 12 .9, 13 .41
Rypnrens nn w sh s nus tvchycard :
17127 .01
17015 .21 6 .2 (3 .1 . 12A)





416.41 3010 .91 6 .64 .9. :!3
.1)
Card ogen c shock 13 )20 .6) 37 (1 .11 17 .1 (8.4, 34 .9)
Hemadynam c comprom se
wth.,
shack 22 134 .9) 353)10 .9) 6.1 (3 .0, 12 .5)





3303 .2) 1,636 150 .0) 1 .1
(0.6. 2 .21
H story of CHF- 416 .4) 88 42 .71 2.4 (0.7, 9.0!
H story ofhypenens nn' 26 041 .91 1 .253138?1 1210.6. 2 .221
H story of d abetes' 171 227.4) 422113 .91 2 .5 (1 .2. 5 .1)
H story of per pheral vascular d sease' 9114 .51 10617 2) 4.811 .9, 11 .71
H story of smok ng' 32156.11 2.533 177 .3) 0.410.2, 0.81
Current smoker'
17129.81
1 .623 149.5) 0
.4 (02 . 0
.91
Abnormal neck ve n d stens on 11117.51 16315 2) 3.8 0 .7 . 8.9)
Heart block (2nd- or 3rd-degree) 7(11 .11 11813 .6) 3.2(1 .2 .8.8)
Any rules present 2-7142.91 509115.5) 3.9 12.1 . 7.5)
S, present 5 (7.9) 121 13.7) 2 .2 10 .7 . 7.1)
Start of r PA s2 h from symptom onset 14(22_.21 846125.8) 0 .610
.4
.1.81
Anter or MI w th STE a6 leads
Yes 19(44.:1 634137.6)
No 24 ( 55.115 1 .053 162.4) 13 50 .6, 2.911
JACC Val. t9. No. 6
May 1992,1129-35
Table 4. Cl n cal Observat ons Dur ng tt-PA Infus on Accord ng
to Occurrence of Early Death 1-1B h)
ep Value from test ng assoc at on between early death (w18 N and pa n
response of pat ents w th m ss
ng data ar amb
guous reta n
. n-PA = recom-
b nmll t ssue-type plasm nogen as va or.
surg cal exam nat on of the chest than among pat ents whose
heart was not d rectly exam ned. Although pat ents n whom
ventr
cular rupture was suspected cl n cally may have un-
dergone autopsy more frequently than other pat ents who
d ed, ventr cular rupture was st ll a less common mechan sm
of early death than was pump fa lure even n autopsy cases.
Thus, although some cases of rupture m ght be m sclass f ed
as deaths due to pump fa lure, pump fa lure would st ll be the
most common mechan sm of death. Th s fnd ng has part c-
ular cl n cal mportance, s nce lethal pump fa lure s a
consequence of mass ve myocard al schem a and necros s
and s thus potent ally preventable or remed able f c rcula-
tory support can be prov ded and myocard al necros s l m-
ted . In contrast, ventr cular rupture n the pat ent who has
rece ved throaaboI t c and ant coagulant drugs s more l kely
to be an unpred ctable and rremed able event .
Prev ous stud es, nclud ng the large Internat onal Study
of
Infarct Surv val (ISIS-1) (15 .161, have suggested that early
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Table 5. Mechan sm of Death Accord ng to T me to Death




cat on of causes of death accord ng to the follow ng rule : all card ac deaths
w th ventrcular rupture present arc attr buted to rupture: n the absence of
mptur card ac deaths w th pump fa lure present are attr buted m pump
future. CABG = coronary artery bypass graft surgery : Ml = myocard al
nfarct on: PICA = pertulaceous translum tml coronary ang oplasty.
n the early hours after acute myocard al nfarct on. In the
control group of that study . the comb
nat on of ventr cular
rupture and electromechan cal d ssoc at on accounted for
50% of card ac deaths dur ng the 1st day 115,16) . 1n TIMI II,
even among autopsy cases, ventr cular rupture was less
common than pump fa
lure . Th s d fference may be due n
part to the nclus on
of
a larger proport on of pat ents w th
nc
p
ent pump fa lure n TIM( 11 .
In ISIS-I the nc dence of lethal ventr cular rupture was
reduced n pat ents treated w th ntravenous atenolol (15).
Although TIMI IIB results do not document a reduct on
n
the frequency ofcard
ac rupture w th mmed ate ntravenous
beta-blocker therapy among pat ents treated w th threm-
bolyt c agents . they do not exclude that poss b l ty .
Pred ct on of early death. The ab l ty to pred ct early
death on the bas s of cl n cal presentat on was l m ted .




rate of early death (13 of 50 pat ents), 22 (6%) of 375 pat ents
w th ev dence of hemodynam c comprom se but w thout
shock exper
enced early death as d
d
28 (1%) of 2,914
pat ents w th m n mal or no hemodynam c comprom se .
Thus . 44% (28 of 63) of the pat ents who d ed early would
have been d ffcult to dent fy, whereas 56% (35 of 63)
could
be cons dered to be at h
gh r sk . The cr ter a of shock or
hemodynam c comprom se would have dent fed 425 (13%)
of t :s 3,339 pat ents n the study who m ght be cons dered
for adjuuct :e or mom aggress ve forms of therapy.
The cl n ced course dur
ng re-PA nfrrsfnn (wh ch was
more frequently nterrupted for pat ents who d ed early than
for others) d d not prov de much further a d . Although only








I Is h-42 day,
(N = 10'-1
Card ovascular d sease
30 27
68
Card acd rnase 30 27 64
Fam1 M( 30 57
Qual fy ng b t 30 27 43
Recurrent 0 0 4
Card ac death`





cular rupture 4 5
9
Other 0 0 I
Compycal ors 2 04 54
Hemorrhage 3 13
Consequence of CADE 0 I 6
Consequence of PICA 0 0 8
Other 0 0 7








In 1911 0 Value
ST segment changes
Normal
zat on only 1(4.81 899!
2 241
0.001
No change reported 49177.81 2,082 163k)
Exacerbat on only 802 71 155 14.71





efofpa n 517 .9) 945 (25 .81 0001'
No change 43168.3) 1 .608 (49.11
Worsen ng 7(31 .1) '-422)7.3(
Absent at Stan
No change 311.81 3 71(0.01
Worsen ng 111 .61 ?9(0.8)
Data m ss ng or amb guous
Mar on dote 2(3.2) '--10.1)
Both rel ef and worsen ng 2 (3.2) 215 (6.51
Rel ef reported when pa n s 111 .61 8 (0. 2_)
ae,cm at n t at on of n-PA
Other cl n
cal obscrval ans
Appearance of new arrhythm as




Resolut on of arrhythm as




Decrease 44 (69.8) 986 (30.11 0 .001
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Table 6. Causes and Mechan
sms of Death Occurr ng <_ 18 h Accord ng to Hemodynam c Status at Study Entry





cular rupture present are aur buted to rupture: n the absence of rupture . card ac deaths w th pump fa lure present are aur buted to pump B ltac . ', No, n
card ogen c shock. but present
ng w
th at least one of the follow ngcond l nne: pulmonary edema . mound
. or thrd-degree atr ocoore cularblock. roles over >Il3
of lung felds or hypotens on w th s nus tucltycard a . CABG = coronary m
sty bypass graft surgery.
8 pat ents had rel ef from chest pa n, the pa n d st nctly
worsened n only 10 pat ents. Normal zat on of ST segment
abnormal t es was uncommon among pat ents dy ng early ;
however, th s f nd ng should be v ewed caut ously, s nce
ascerta nment of [h s event requ
red [hat pat ents surv ve
unt l a second electrocard ogram (ECG) could be performed .
The appearance of hypotens on or worsen ng arrhylhm as
was an om nous prognost c s gn, but these events are non-
spec fc features of card ac decompensat on and arrest : the r
or g
ns often cannot be separated from agonal events . How-
ever, of 44 pat ents n whom a decrease n blood pressure
was noted, 43 (98%) surv ved >30 m n and 23 (>50%)
surv ved >2 h after th s determ nat on . Such a fnd ng m ght
allow t me for emergency ang ography and mod fcat on of a
planned management strategy
.
Therapeut c mplcat ons . Further reduct on n mortal ty
among pat ents rece
v
ng thrombolyt c therapy for acute
myocard al nfarct on s poss ble . The most common mech-
an
sm of death was pump fa lure rather than ventr cular
rupture or bleed
ng. Both enzymat c and patholog c stud es
(17,18) of pat ents w th card
ogen c shock have shown that
necros s s a frogress vc rather than an nstantaneous pro-
cess when large areas of myocard um are nvolved. Whether
pump fa lure was a consequence of fa lure to ach eve and
susta n reperfus on or of the nab
l
ty of the dysfunct onal
("stunned") or necrot c myocard um to ma nta n the card ac
output even n the presence of restored anterograde flow s
not known
. If the former, then more v gorous thrombolyt c,
ant thrombot c or ant platelet therapy or mechan
cal revas-
cular zat on would seem to he nd cated . If the latter, tem-
porary mechan cal hemodynam c support m ght be helpful .
G ven that hemodynam c collapse preceded death by >2 h n
>50% of the pat ents who d ed early, aggress ve use of
notrop
c agents or mp.ementat on of such dev ces as n-
traaort
c balloon couuterputsat on or extracorporeal
ventrc-
ular
support m ght be useful
t-, allow
ng t
me for reperfus on
to occur or for dysfunct onal myocard um to recover .
Role of reperfus on. Data from controlled tr als (7 .8) have
suggested that death w th





on may not be prevented by adm n strat on of throm-
bolyt c agents. Whether th s p);enomenon represents fa lure
of these drugs to produce reperfus on s not known. Other
stud es 119-211 of thrombolyt
c therapy
nd cate that fa
lure
to ach eve and ma nta n patenl:y of the nfarct-related artery
s a strong pred ctor of death both n the hosp tal and after
d scharge . Extens on of th s f nd ng to pat ents who d e early
would requ re rout ne early coronary ang ography, wh ch
was not pan of the TIMI If protocol. Although t would seem
reasonable that early mortal ty s more l kely n pat ents w th
unsuccessful reperfus on therapy, TIMI 11 data do not ad-
dress th s hypothes s. Several reports (22,23) have nd cated
that death from pump fa lure may even follow successful
reperfus on . In an analys s of 500 pat ents undergo ng ang o-
plasly as treatment for acute myocard al
nfarct
on, Ell s et
al. (24) reported that even among th s group, 45% of deaths
occurred w th n the 1st 24 h after card ac catheter zat on .
Although TIM] IIA and other stud es (19,24-26) have shown
the detr
mental effect of the rout ne appl
cat
on of ang o-
plasty after Ihrombolys s . observat ons of favorable exper -
ences w th successful ang oplasty for pat ents n card ogen c
shock (27-30) suggest that select ve appl
cat
on of such
therapy m ght reduce the r sk of early death f appropr ate
cand dates could be dent f ed. Among pat ents present ng
w
th m nor or no hemodynam c comprom se, only 39% of
early deaths were assoc ated w th pump fa lure, and other
causes of death may prove less amenable to ntervent on .
Role of adjunct ve strateg es. Seventy-fve percent of pa-
t ents n our cohort who d ed early had a frst nfarct on,
whereas only 8% had prev ous congest ve heart fa lure .
Rather than represent ng a mor bund group w th preex st ng
severe heart damage, those pat ents who d ed w
th
n the 1st
I8 h are a group who potent ally stand to beneft from
develop ng adjunct ve strateg es.
Our fnd ngs also suggest that further advances n med cal
and hemodynam c support that can be read ly ava lable to all
pat ents may be of use . These
nclude earl er access to
treatment ( nclud ng adm n strat on of thrombolyt c drugs
before the hosp tal stay) and earl er ava lab l ty of hemody-
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nam c support for pat ents w th nc p ent pump fa lure . The
f nd ng that a relat vely large proport on of early deaths
occurred before a full dose of rt-PA could be g ven would
support the concept of rap d adm n strat on or "front load-
ng"
of
thrombolyt c therapy (31) .
If early rcperfus on does
l m t ca ly mortal ty, t s conce vable that some early deaths
m ght he averted by the earl er occurrence of reperfus on
that has been reported w th such reg mens. It s also poss
ble
that some of the early deaths occurred n pat ents n whom
reperfus on m ght have succeeded had not the act on of
rt-PA been nterrupted . Th s suggest on should be regarded
as speculat ve, s
nce t s not known whether the early





on of the present study s that
resources should be devoted to mprov ng access to throm-
bolys s. Although the mean t me to treatment n the TIMI II
tr al (8) was relat vely short (2 .6 h) by current standards, and
22% of pat ents w th early death rece ved rt-PA w th n 2 h
after the onset of symptoms . many of the pat ents who d
ed
early had s gns of congest ve heart fa lure when therapy was
n t ated . Thus, for thf . ;e paHrnrs, even "early" therapy was
not early enough.
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